[Event] 6th Annual Conference .
This event has ended.
2022/09/14 Added announcement video
2022/09/06 Added luncheon mini-seminar
——
The 6th Annual Meeting will be held as follows.
This year, the conference will be held simultaneously at the venue and online.
Please be careful when coming to the venue as a typhoon is approaching.
Date and Time
Sunday, September 18, 2022
Opening at 11:00 am (doors open at 10:30 am) – Closing at 5:00 pm
*The general meeting will be held from 9:00 to 10:30 (members only).
venue
Rihga Royal Hotel Osaka West Wing 2F “Yamaraku no Ma”
5-3-68 Nakanoshima, Kita-ku, Osaka 530-0005, Japan
TEL: (06) 6448-1121
Access here
Free shuttle bus from JR Osaka here
Parking information
Greetings from the Representative Director
General Incorporated Foundation Cho The Endoflora Transplant Clinical Research Group was able to welcome its 6th academic conference. We would like to express our gratitude to the patients who underwent transplantation, the doctors and other medical professionals belonging to the study group, supporting members, and the general public for their support and cooperation. Our research group is the first and only private organization in Japan to systematically engage in intestinal flora transplantation. In order to fulfill our social contribution with pride as a clinician, we will work together with various experts to advance basic and clinical research, steadily transmit information to society, and aim for further development. Following our work on ASD, we also plan to work on verifying the safety and effectiveness of FMT in inflammatory bowel diseases, kidney diseases, allergic diseases, etc. Our research group will continue to make further efforts to contribute to society through research on intestinal bacteria, intestinal flora transplantation, disease treatment, prevention, health maintenance, and the goal of happiness in life. I’m thinking of coming. We appreciate your continued support and cooperation.
Registration and Participation Fee
On-site registration is due by noon on Thursday, September 15.
Online registration is due by noon on Friday, September 16.
Please note that no cancellations will be accepted after the deadline for both on-site and online registration.
Applications are no longer being accepted
Both on-site and online participation is free for transplant patients.
If you wish to view only the afternoon abstracts, you may view the Keynote Speech, Case Reports, and Panel Discussion on Autism Spectrum Disorders free of charge. Please
register for both to receive the URL.
time schedule
| 10:30 | inauguration |
| 11:00 | Opening Remarks Dr. Zen Tanaka, Representative Director (President, Tanaka Clinic, Jinzenkai Medical Corporation) |
| Efforts for Renal Diseases “Future Clinical Research in the Intestinal Flora Transplantation Clinical Study Group – Efforts for Renal Diseases” Dr. Zen Tanaka (President, Tanaka Clinic, Jinzenkai Medical Corporation) “Study on Safety and Effectiveness of Intestinal Flora Transplantation in Dogs and Cats with Chronic Kidney Disease” Dr. Shosei Toyofuku (Director, Hyogo Minato Animal Hospital, Hyogo, Japan) ) |
|
| 11:30～11:50 | Inflammatory Bowel Disease Case Report “A case of irritable bowel syndrome and ulcerative colitis in which intestinal flora transplantation was effective” Dr. Mamoru Kimura (President, Kimura Hospital, Medical Corporation Keimeikai) |
| 11:55-12:15 | NanoGAS ® Water Basic Research Presentation “Innovative Material: Exploring the Utilization of NanoGAS ® in the Pharmaceutical and Food Fields” Risako Morishita (Symbiosis Inc.) |
| 12:15～13:15 | Lunch Break (box lunch available) Luncheon Mini Seminar “Gut Bacteria Pleasing Carbohydrates – Possibilities of Fermented Seasonings” Ms. Ai Kitamura (Fermented Food Specialist / President, Love I Food Education, Inc.) Introduction of Supporting Companies |
| 13:20～14:20 | Keynote Speech “How to Use the Accumulation of Scientific Knowledge on Autism Spectrum Disorders (ASD) – From Research to Clinical Practice” Lecturer: Dr. Kenji Tsuchiya Specially Appointed Professor, Research Center for Child Mental Development, Hamamatsu University School of Medicine |
| 14:20～14:50 | ASD case report “Case report of FMT using NanoGAS® for ASD” Dr. Masahiko Johya (Director, Luke’s Ashiya Clinic) |
| 15:00～16:00 | Panel Discussion and Q&A “The Future of Children with Autism Spectrum Disorders” Panelists: Dr. Kenji Tsuchiya (Specially Appointed Professor, Research Center for Child Mental Development, Hamamatsu University School of Medicine) Dr. Taiichi Katayama (Vice Dean, United Graduate School of Medicine) Child Development, Osaka University / Professor, Molecular Biogenetics Research Area) Dr. Masahiko Johya (Director, Luke’s Ashiya Clinic) Ms. Naomi Hatanaka (President, Challenged LIFE Incorporated Association) |
| 16:00～16:20 | Prospects for NanoGAS ® Water Research “About the Future of NanoGAS ® -FMT” Makoto Shimizu, Senior Researcher, Symbiosis, Inc. |
| 16:20～16:50 | Future Initiatives “Possibility of Intestinal Flora Transplantation” Dr. Kunihiro Kitamura (President, Kitamura Clinic, Medical Corporation Kiwakai) Dr. Reiko Haruna (Vice President, Haruna Clinic, Medical Corporation Haruna) Dr. Shoko Arisawa (Director, Hoshigaoka Dermatology Clinic, Medical Corporation Aiseikai) Dr. Yuichi Kawai (President, Cute Medicine Clinic, Medical Corporation Yuuakai) Director) |
| 16:50 | Closing Remarks Executive Director Dr. Masahiko Johya (Director, Luke’s Ashiya Clinic) |
Speakers Renal Disease Initiatives
Renal Disease Initiatives
Corporation Chairman 
Our research group has been conducting clinical research on intestinal flora transplantation (FMT) to treat not only gastrointestinal diseases such as ulcerative colitis and irritable bowel syndrome, but also children. It has been successful in treating autism spectrum disorder and allergic diseases such as atopic dermatitis. In the future, we would like to proceed with clinical verification for kidney diseases. From the perspective of entero-renal linkage, FMT may be able to suppress the decline in renal function in patients with pre-dialysis renal failure for whom no active treatment is available. This time, I would like to raise an issue regarding the application of FMT to kidney diseases.
Hospital Director 
Fecal microbial transplantation (FMT) in veterinary medicine has been reported in a wide range of animal species including dogs, cats, pigs, horses, cows, chickens, and monkeys, and it is still a treatment method with a high level of evidence. Although it cannot be said that this is the case, it has been suggested that it may be an effective treatment. Chronic kidney disease (CKD) is a disease commonly encountered in dogs and cats, with a particularly high prevalence in older cats, and is generally treated with therapeutic diet, fluid therapy, and drug therapy. I recently had the opportunity to perform FMT on dogs and cats with CKD, so I would like to report on the progress.
Inflammatory bowel disease case report
Hospital Chairman 
Fecal microbial transplantation (FMT) is expected to be a method to improve dysbiosis in the intestinal flora. The Intestinal Flora Transplant Clinical Research Group performs FMT transplantation (NanoGAS®-FMT) using nanobubble water containing dissolved microbubbles. This time, we will report on the usefulness, safety, and simplicity of the procedure for cases of ulcerative colitis and irritable bowel syndrome in which NanoGAS®-FMT was performed at our hospital, which is responsible for primary care in the region.
NanoGAS Water Basic Research Presentation
Symbiosis Co., Ltd.
NanoGAS® (Nanobubble) not only has the ability to retain gas in liquid for long periods of time, but also has high potential as a multifunctional material for living organisms. Nanobubbles have begun to be used in cleaning and various industries, but their usefulness in the health science field is still under development. By advancing basic research while understanding the unique physicochemical properties that make NanoGAS so appealing, we are exploring the possibility of NanoGAS® becoming a “new modality” in the pharmaceutical and medical fields. This year, we also focused on the food processing industry and clarified the usefulness of NanoGAS® for general use. This time, I would like to summarize and report the research results of the past two years.
Luncheon Mini Seminar
/Representative director of LOVE I FOOD EDUCATION general incorporated association
One of the things you should avoid when thinking about your intestines is “refined sugar.” Nowadays, you can always buy sweets at convenience stores. “I want to eat sweets, but I want to avoid them, what should I do? ” There are many people who have such problems. I also loved sweets, but the reason I was able to quit sweets was because of amazake. Amazake is rich in oligosaccharides and fermented metabolites, and is a sugar content that is good for the intestines. You can make delicious sweets using the amazake, and it can also be used in cooking. We will tell you the charm of fermented seasonings.
Keynote Speech
The prevalence of autism spectrum disorder (ASD), a neurodevelopmental disorder (developmental disorder), in children is 2 to 3%. In recent years, social understanding of “developmental disabilities” and “autism spectrum disorders” has expanded, and awareness of reasonable accommodation has also increased. However, the cause of ASD remains unknown, and no biological treatments have established efficacy. Therefore, in order to interact with children and individuals with ASD in clinical settings, we are required to have insight and vision regarding how to develop and utilize limited knowledge, know-how, and techniques. This lecture will attempt to summarize recent scientific findings regarding the clinical characteristics of ASD and its biological and physiological background. We will also introduce how ASD is diagnosed in clinical settings and what kind of therapeutic interventions are used for children with ASD. We will then discuss how “scientific knowledge” and “realistic practice in clinical settings” should be blended, with a particular focus on how to diagnose ASD.
ASD case report
Ashiya Clinic Director 
The cause of autism spectrum disorder (ASD) has not yet been identified, and no drastic treatment has been established yet. In recent years, it has become clear that dysbiosis in the intestinal flora is associated with the symptoms of ASD. The effectiveness and safety of correcting this problem has been debated. Since the founding of our research group in 2017, we have been performing FMT using NanoGAS® water for ASD, and there have been cases where symptoms such as tantrums and poor switching were alleviated immediately after FMT. I have experienced cases where communication has improved. This time, we will discuss the trends in the intestinal flora, which we believe are characteristic of ASD, and review literature on ASD cases in which FMT using NonaGAS® was effective.
panel discussion
“The Future of Children with Autism Spectrum Disorders”
Panelists
Dr. Kenji Tsuchiya (Specially Appointed Professor, Research Center for Child Mental Development, Hamamatsu University School of Medicine)
Dr. Taiichi Katayama (Vice Dean, United Graduate School of Child Development, Osaka University / Professor, Division of Molecular Biogenetics)
Dr. Masahiko Johya (Director, Luke’s Ashiya Clinic)
Ms. Naomi Hatanaka (General Incorporated Association Challenge (Representative Director, Challenged LIFE)
Click here to see a message from Naomi Hatanaka, President of Challenged LIFE, a general incorporated association, about the academic conference:
(short video: about 1 minute)
Prospects for NanoGAS Water Research
The earliest origin of intestinal flora transplantation was in China around the 4th century, when feces from a healthy person was put into the buttocks of a person who had persistent diarrhea, which cured the diarrhea. It is said to be a treatment example. Time has passed since then, and research on fecal microorganism transplantation (intestinal flora transplantation) has progressed in Western countries, starting with a report on pseudomembranous enteritis in 1958. In 2013, a Dutch study found that it was effective in treating Clostridioides difficile infection (CDI), and in 2014 the U.S. Food and Drug Administration (FDA) announced that “intestinal flora transplantation should be used to treat multidrug resistance in CDI.” It is positioned as the first treatment of choice, and its effectiveness is being proven medically. We have commercialized a technology that allows other people’s intestinal bacteria to colonize the recipient’s intestinal mucosa layer without using antibiotics, using our unique patented technology, NanoGAS®, to dissolve stool. The next goal is to purify a bacterial solution for transplantation in an environment as close as possible to the intestinal tract. We will talk about the development of the world’s first automatic bacterial liquid purification device “Monotone” and our future goal, NanoGAS®-FMT.
[updated history].
2022/08/31 Added the content of the speech
2022/08/18 Added time schedule
2022/08/09 Added details of ASD case reports
2022/08/01 Added details of Keynote Speech
2022/06/30 Registration is now open
その他の events に関する記事
Articles about other events
April 03, 2024
【Event】 Dr. Shirotani will speak at the 7th Annual Conference of the Japanese Society of Preemptive Clinical Medicine
Dr. Masahiko Shirotani, Executive Director of the Luke’s Ashiya Clinic, will deliver a special lecture at the 7th Annual Conference of the Japanese Society of Preemptive Medicine to be held on June 22 (Sat.) and 23 (Sun.), 2024. Dr. Zen Tanaka, President of Tanaka Clinic, Nizenkai Medical Corporation, will be the chairperson. Lecture Contents Special […]
March 04, 2024
〈Registration Start〉8th Annual Conference
We are pleased to announce that the 8th Annual Conference will be held again this year. (Venue and online)Anyone is welcome to attend, not only healthcare professionals, but also the general public, students, etc. Date and Time Sunday, September 22, 2024Start 11:00 am (Registration 10:30 am) – Closing at 5:00 pm *General Meeting: Held before […]
September 27, 2023
第7回学術大会【開催報告】
The “7th Academic Conference” was held on Sunday, September 17, 2023. The event was held simultaneously at the venue and online, and was attended by a large number of people, including medical professionals, general companies, research institutions, patients, and the general public. I would like to take this opportunity to express my gratitude to all […]
